Stocks News

LAST PRICE
32.8950
TODAY'S CHANGE (%)
Trending Down-2.6050 (-7.3380%)

Bid / Lots
32.1000/ 1
Ask / Lots
34.2300/ 1
Open / Previous Close
35.8300 / 35.5000
Day Range
Low 32.5310
High 35.8300
52 Week Range
Low 25.7700
High 50.2300
Volume
754,729
above average

Search Criteria

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
Company	Country	Symbol

TD Direct Investing offers more research reports than any other discount brokerage in Canada. Provided from the industry's most trusted sources, our service includes timely, relevant information for the current trading day and comprehensive industry, sector, and insider trading reports for further analysis.

Open a New Account, or Login if you're a client.

Nov 13, 2024
- DJ CG Oncology Price Target Maintained With a $75.00/Share by HC Wainwright & Co., from 7:14AM ET on Wednesday Nov 13, 2024 by Dow Jones
  7:14AM ET on Wednesday Nov 13, 2024 by Dow Jones
  Companies Mentioned: CGON
  
  Ratings actions from Benzinga: https://www.benzinga.com/quote/CGON/analyst-ratings
  
  (END) Dow Jones Newswires
  
  November 13, 2024 07:14 ET (12:14 GMT)
Nov 12, 2024
- CG Oncology's Q3 Loss Narrows, from 9:01AM ET on Tuesday Nov 12, 2024 by MT Newswires
  9:01AM ET on Tuesday Nov 12, 2024 by MT Newswires
  Companies Mentioned: CGON
  09:01 AM EST, 11/12/2024 (MT Newswires) -- CG Oncology (CGON) reported a Q3 loss Tuesday of $0.30 per diluted share, narrower than a loss of $4 a year earlier. Analysts polled by Capital IQ expected a loss of $0.38. As expected, no revenue for the q...
- Press Release: CG Oncology Reports Third Quarter 2024 Financial Results and Provides Business Updates, from 8:00AM ET on Tuesday Nov 12, 2024 by Dow Jones
  8:00AM ET on Tuesday Nov 12, 2024 by Dow Jones
  Companies Mentioned: CGON
- CG Oncology Reports Third Quarter 2024 Financial Results and Provides Business Updates, from 8:00AM ET on Tuesday Nov 12, 2024 by Dow Jones
  8:00AM ET on Tuesday Nov 12, 2024 by Dow Jones
  Companies Mentioned: CGON
  
  CG Oncology Reports Third Quarter 2024 Financial Results and Provides Business Updates
  
  - Late-Breaking Abstract on Results of Phase 3 BOND-003 Trial of Cretostimogene Monotherapy in BCG-Unresponsive NMIBC Accepted at the Society of Urologic Oncology (SUO) 25th Annual Meeting -
- DJ CG Oncology Price Target Maintained With a $75.00/Share by HC Wainwright & Co., from 6:29AM ET on Tuesday Nov 12, 2024 by Dow Jones
  6:29AM ET on Tuesday Nov 12, 2024 by Dow Jones
  Companies Mentioned: CGON
  
  Ratings actions from Benzinga: https://www.benzinga.com/quote/CGON/analyst-ratings
  
  (END) Dow Jones Newswires
  
  November 12, 2024 06:29 ET (11:29 GMT)

Nov 14, 2024
- Soleno Therapeutics Announces Oral Presentations featuring Diazoxide Choline Extended-Release (DCCR) Tablets in Prader-Willi Syndrome at ESPE 2024, from 4:05PM ET on Thursday Nov 14, 2024 by Dow Jones
  4:05PM ET on Thursday Nov 14, 2024 by Dow Jones
  Companies Mentioned: SLNO
Nov 12, 2024
- SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates B, LBPH, ZUO on Behalf of Shareholders, from 1:20PM ET on Tuesday Nov 12, 2024 by PR Newswire
  1:20PM ET on Tuesday Nov 12, 2024 by PR Newswire
  Companies Mentioned: ZUO, B, LBPH
- SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates B, LBPH, ZUO on Behalf of Shareholders, from 1:20PM ET on Tuesday Nov 12, 2024 by Dow Jones
  1:20PM ET on Tuesday Nov 12, 2024 by Dow Jones
  Companies Mentioned: ZUO, B, LBPH
- Longboard Pharmaceuticals Initiates Phase 3 DEEp OCEAN Study Evaluating Bexicaserin in Developmental and Epileptic Encephalopathies (DEEs), from 8:30AM ET on Tuesday Nov 12, 2024 by Dow Jones
  8:30AM ET on Tuesday Nov 12, 2024 by Dow Jones
  Companies Mentioned: LBPH
Nov 11, 2024
- Geron Corporation Announces Appointment of Joseph Eid, M.D. as Executive Vice President, Research and Development, from 4:30PM ET on Monday Nov 11, 2024 by Dow Jones
  4:30PM ET on Monday Nov 11, 2024 by Dow Jones
  Companies Mentioned: GERN
- Geron to Participate in the Stifel 2024 Healthcare Conference, from 9:00AM ET on Monday Nov 11, 2024 by Dow Jones
  9:00AM ET on Monday Nov 11, 2024 by Dow Jones
  Companies Mentioned: GERN
- DJ Soleno Therapeutics Price Target Maintained With a $70.00/Share by HC Wainwright & Co., from 6:28AM ET on Monday Nov 11, 2024 by Dow Jones
  6:28AM ET on Monday Nov 11, 2024 by Dow Jones
  Companies Mentioned: SLNO
Nov 7, 2024
- Longboard Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Corporate Updates, from 4:01PM ET on Thursday Nov 07, 2024 by Dow Jones
  4:01PM ET on Thursday Nov 07, 2024 by Dow Jones
  Companies Mentioned: LBPH
- Press Release: Longboard Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Corporate Updates, from 4:01PM ET on Thursday Nov 07, 2024 by Dow Jones
  4:01PM ET on Thursday Nov 07, 2024 by Dow Jones
  Companies Mentioned: LBPH
- Geron Secures up to $375 Million in Funding with Royalty Pharma, Pharmakon Advisors, from 11:42AM ET on Thursday Nov 07, 2024 by MT Newswires
  11:42AM ET on Thursday Nov 07, 2024 by MT Newswires
  Companies Mentioned: GERN, RPRX

CG Oncology Inc
NASDAQ:CGONUnited States

Search Criteria

Nov 13, 2024

DJ CG Oncology Price Target Maintained With a $75.00/Share by HC Wainwright & Co., from 7:14AM ET on Wednesday Nov 13, 2024 by Dow Jones

Nov 12, 2024

CG Oncology's Q3 Loss Narrows, from 9:01AM ET on Tuesday Nov 12, 2024 by MT Newswires

Press Release: CG Oncology Reports Third Quarter 2024 Financial Results and Provides Business Updates, from 8:00AM ET on Tuesday Nov 12, 2024 by Dow Jones

CG Oncology Reports Third Quarter 2024 Financial Results and Provides Business Updates, from 8:00AM ET on Tuesday Nov 12, 2024 by Dow Jones

DJ CG Oncology Price Target Maintained With a $75.00/Share by HC Wainwright & Co., from 6:29AM ET on Tuesday Nov 12, 2024 by Dow Jones

Peers Headlines

Nov 14, 2024

Soleno Therapeutics Announces Oral Presentations featuring Diazoxide Choline Extended-Release (DCCR) Tablets in Prader-Willi Syndrome at ESPE 2024, from 4:05PM ET on Thursday Nov 14, 2024 by Dow Jones

Nov 12, 2024

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates B, LBPH, ZUO on Behalf of Shareholders, from 1:20PM ET on Tuesday Nov 12, 2024 by PR Newswire

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates B, LBPH, ZUO on Behalf of Shareholders, from 1:20PM ET on Tuesday Nov 12, 2024 by Dow Jones

Longboard Pharmaceuticals Initiates Phase 3 DEEp OCEAN Study Evaluating Bexicaserin in Developmental and Epileptic Encephalopathies (DEEs), from 8:30AM ET on Tuesday Nov 12, 2024 by Dow Jones

Nov 11, 2024

Geron Corporation Announces Appointment of Joseph Eid, M.D. as Executive Vice President, Research and Development, from 4:30PM ET on Monday Nov 11, 2024 by Dow Jones

Geron to Participate in the Stifel 2024 Healthcare Conference, from 9:00AM ET on Monday Nov 11, 2024 by Dow Jones

DJ Soleno Therapeutics Price Target Maintained With a $70.00/Share by HC Wainwright & Co., from 6:28AM ET on Monday Nov 11, 2024 by Dow Jones

Nov 7, 2024

Longboard Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Corporate Updates, from 4:01PM ET on Thursday Nov 07, 2024 by Dow Jones

Press Release: Longboard Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Corporate Updates, from 4:01PM ET on Thursday Nov 07, 2024 by Dow Jones

Geron Secures up to $375 Million in Funding with Royalty Pharma, Pharmakon Advisors, from 11:42AM ET on Thursday Nov 07, 2024 by MT Newswires